CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
CytomX Therapeutics announced strong Q1 2026 financial results alongside positive clinical data from its Phase 1 dose expansion study of Varseta-M, an EpCAM-targeted PROBODY ADC for advanced colorectal cancer. The company completed enrollment for dose optimization and plans additional combination and expansion studies. Financially, CytomX raised $2…